Understanding how MAP2 affects nerve damage from chemotherapy
Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11006261
This study is looking at how a protein called MAP2 might help protect nerves from damage caused by chemotherapy drugs, which can lead to uncomfortable side effects for cancer patients, and it uses special lab techniques to better understand this process.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11006261 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a protein called MAP2 in causing nerve damage related to chemotherapy, known as chemotherapy-induced peripheral neuropathy (CIPN). By using human-derived nerve cells, the researchers will explore how chemotherapy drugs like bortezomib, paclitaxel, and vincristine affect MAP2 levels and its localization within the cells. The study aims to understand the mechanisms behind nerve damage and how enhancing MAP2 levels could potentially protect against this side effect. This innovative approach includes using advanced genetic engineering techniques to create modified nerve cells for detailed analysis.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving chemotherapy and experiencing symptoms of peripheral neuropathy.
Not a fit: Patients who are not undergoing chemotherapy or do not experience peripheral neuropathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or reducing nerve damage in patients undergoing chemotherapy.
How similar studies have performed: Previous research has shown promising results in understanding nerve damage mechanisms related to chemotherapy, but this specific approach using MAP2 is novel.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STAFF, NATHAN P — MAYO CLINIC ROCHESTER
- Study coordinator: STAFF, NATHAN P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.